Cardiac amyloidosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 22: | Line 22: | ||
*Senile type of cardiac amyloidosis typically presents after 60 years of age, most commonly after 70 years of age. | *Senile type of cardiac amyloidosis typically presents after 60 years of age, most commonly after 70 years of age. | ||
* Various mutations of proteins involved in amyloid deposition may present anytime between 30 to 70 years of age. | * Various mutations of proteins involved in amyloid deposition may present anytime between 30 to 70 years of age. | ||
*The incidence and prevalence of cardiac amyloisosis | *The [[incidence]] and [[prevalence]] of cardiac amyloisosis have significantly increased among the elderly after 2006.<ref name="pmid311708025">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref> | ||
===Ethnicity=== | ===Ethnicity=== | ||
* 3-4% of African-Americans carry the most common mutation that causes the substitution of Ile for Val at position 122 <ref name="pmid6278822">{{cite journal |author=Dictor M, Hasserius R |title=Systemic amyloidosis and non-hematologic malignancy in a large autopsy series |journal=[[Acta Pathologica Et Microbiologica Scandinavica. Section a, Pathology]] |volume=89 |issue=6 |pages=411–6 |year=1981 |month=November |pmid=6278822 |doi= |url= |accessdate=2012-02-13}}</ref> and is known to contribute to the incidence of [[Cardiac amyloidosis pathophysiology#Hereditary Transthyretin (TTR)-Related Form (ATTR)|familial amyloidotic cardiomyopathy]].<ref name="pmid8698351">{{cite journal |author=Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN |title=Revised transthyretin Ile 122 allele frequency in African-Americans |journal=[[Human Genetics]] |volume=98 |issue=2 |pages=236–8 |year=1996 |month=August |pmid=8698351 |doi= |url=http://link.springer.de/link/service/journals/00439/bibs/6098002/60980236.htm |accessdate=2012-02-13}}</ref> | * 3-4% of African-Americans carry the most common mutation that causes the substitution of Ile for Val at position 122 <ref name="pmid6278822">{{cite journal |author=Dictor M, Hasserius R |title=Systemic amyloidosis and non-hematologic malignancy in a large autopsy series |journal=[[Acta Pathologica Et Microbiologica Scandinavica. Section a, Pathology]] |volume=89 |issue=6 |pages=411–6 |year=1981 |month=November |pmid=6278822 |doi= |url= |accessdate=2012-02-13}}</ref> and is known to contribute to the incidence of [[Cardiac amyloidosis pathophysiology#Hereditary Transthyretin (TTR)-Related Form (ATTR)|familial amyloidotic cardiomyopathy]].<ref name="pmid8698351">{{cite journal |author=Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN |title=Revised transthyretin Ile 122 allele frequency in African-Americans |journal=[[Human Genetics]] |volume=98 |issue=2 |pages=236–8 |year=1996 |month=August |pmid=8698351 |doi= |url=http://link.springer.de/link/service/journals/00439/bibs/6098002/60980236.htm |accessdate=2012-02-13}}</ref> | ||
* After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States.<ref name="pmid9017939">{{cite journal |author=Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN |title=Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans |journal=[[The New England Journal of Medicine]] |volume=336 |issue=7 |pages=466–73 |year=1997 |month=February |pmid=9017939 |doi=10.1056/NEJM199702133360703 |url=http://dx.doi.org/10.1056/NEJM199702133360703 |accessdate=2012-02-13}}</ref> | * After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States.<ref name="pmid9017939">{{cite journal |author=Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN |title=Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans |journal=[[The New England Journal of Medicine]] |volume=336 |issue=7 |pages=466–73 |year=1997 |month=February |pmid=9017939 |doi=10.1056/NEJM199702133360703 |url=http://dx.doi.org/10.1056/NEJM199702133360703 |accessdate=2012-02-13}}</ref> | ||
*The incidence and prevalence of cardiac amyloidosis have increased among blacks from 2000 to 2012.<ref name="pmid311708026">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref> | |||
===Gender=== | ===Gender=== | ||
Revision as of 03:08, 4 November 2019
|
Cardiac amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac amyloidosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cardiac amyloidosis epidemiology and demographics |
|
Cardiac amyloidosis epidemiology and demographics in the news |
|
Risk calculators and risk factors for Cardiac amyloidosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
There were 4746 incident cases of cardiac amyloidosis in 2012 and 15 737 prevalent cases in 2012. There was also a significant increase in the prevalence rate (8 to 17 per 100 000 person-years) and incidence rate (18 to 55 per 100 000 person-years) from 2000 to 2012, most notable after 2006. Incidence and prevalence increased substantially more among men, the elderly, and in blacks.
Epidemiology and Demographics
Incidence
- The incidence rate increased from 18 to 55 per 100,000 person-years from 2000 to 2012.[1]
- There were 4746 incident cases of cardiac amyloidosis in the US in 2012.[2]
Prevalence
- The prevalence rate increased from 8 to 17 per 100 000 person-years from 2000 to 2012.[3]
- There were 15,737 prevalent cases in 2012.
Age
- In the United States, it has been estimated that there are 1.3 million gene carries and that there are approximately 150,000 carriers over the age of 60 years.
- Cardiac amyloidosis commonly presents in adults more than 40 years old.
- Senile type of cardiac amyloidosis typically presents after 60 years of age, most commonly after 70 years of age.
- Various mutations of proteins involved in amyloid deposition may present anytime between 30 to 70 years of age.
- The incidence and prevalence of cardiac amyloisosis have significantly increased among the elderly after 2006.[4]
Ethnicity
- 3-4% of African-Americans carry the most common mutation that causes the substitution of Ile for Val at position 122 [5] and is known to contribute to the incidence of familial amyloidotic cardiomyopathy.[6]
- After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States.[7]
- The incidence and prevalence of cardiac amyloidosis have increased among blacks from 2000 to 2012.[8]
Gender
- There is no difference in the incidence of cardiac amyloidosis between men and women as it affects both genders equally.
- Over the years, both incidence and prevalence of cardiac amyloidosis have increased among men.[9]
References
- ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
- ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
- ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
- ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
- ↑ Dictor M, Hasserius R (1981). "Systemic amyloidosis and non-hematologic malignancy in a large autopsy series". Acta Pathologica Et Microbiologica Scandinavica. Section a, Pathology. 89 (6): 411–6. PMID 6278822. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN (1996). "Revised transthyretin Ile 122 allele frequency in African-Americans". Human Genetics. 98 (2): 236–8. PMID 8698351. Retrieved 2012-02-13. Unknown parameter
|month=ignored (help) - ↑ Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997). "Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans". The New England Journal of Medicine. 336 (7): 466–73. doi:10.1056/NEJM199702133360703. PMID 9017939. Retrieved 2012-02-13. Unknown parameter
|month=ignored (help) - ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
- ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.